View ValuationRedcare Pharmacy 향후 성장Future 기준 점검 4/6Redcare Pharmacy (는) 각각 연간 55.1% 및 10.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 54% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11.6% 로 예상됩니다.핵심 정보55.1%이익 성장률54.04%EPS 성장률Consumer Retailing 이익 성장10.0%매출 성장률10.6%향후 자기자본이익률11.62%애널리스트 커버리지Good마지막 업데이트19 Jun 2026최근 향후 성장 업데이트Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updatesRecent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.공시 • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.공시 • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026공시 • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.공시 • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026공시 • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.Reported Earnings • Oct 30Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €719.2m (up 25% from 3Q 2024). Net loss: €7.24m (loss widened 4.8% from 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Europe.New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Significant insider selling over the past 3 months (€307k sold).공시 • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025공시 • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.Reported Earnings • Jul 29Second quarter 2025 earnings released: EPS: €0.46 (vs €0.21 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.46 (up from €0.21 loss in 2Q 2024). Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up €13.6m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.공시 • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025공시 • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.이익 및 매출 성장 예측BIT:1RDC - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20284,1785145121812/31/20273,793161185812/31/20263,401-16-344883/31/20263,073-37-10217N/A12/31/20252,941-38-8831N/A9/30/20252,821-35-6233N/A6/30/20252,676-35-3644N/A3/31/20252,528-48-1538N/A12/31/20242,371-45-2022N/A9/30/20242,227-25-1131N/A6/30/20242,128-9-833N/A3/31/20241,987-10038N/A12/31/20231,799-122361N/A9/30/20231,595-16-240N/A6/30/20231,404-45-1333N/A3/31/20231,272-65-59-9N/A12/31/20221,204-78-83-29N/A9/30/20221,165-110-68-16N/A6/30/20221,118-105-481N/A3/31/20221,081-91-406N/A12/31/20211,060-74-3212N/A9/30/20211,037-39-1435N/A6/30/20211,038-29-2827N/A3/31/20211,020-18-1735N/A12/31/2020968-17-3618N/A9/30/2020895-15-56-19N/A6/30/2020827-20-43-19N/A3/31/2020758-27-38-16N/A12/31/2019701-36N/A-31N/A9/30/2019660-41N/A-11N/A6/30/2019621-40N/A-10N/A3/31/2019584-40N/A-26N/A12/31/2018540-34N/A-15N/A9/30/2018481-31N/A-31N/A6/30/2018415-28N/A-24N/A3/31/2018351-24N/A-17N/A12/31/2017284-21N/A-23N/A9/30/2017244-22N/A-11N/A6/30/2017222-20N/A-16N/A3/31/2017200-20N/A-14N/A12/31/2016177-18N/A-17N/A9/30/2016159-13N/A-5N/A6/30/2016147-13N/A-5N/A3/31/2016136-12N/A-7N/A12/31/2015126-11N/A-9N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 1RDC 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.3%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 1RDC (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 1RDC 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 1RDC 의 수익(연간 10.6%)이 Italian 시장(연간 6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 1RDC 의 수익(연간 10.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 1RDC의 자본 수익률은 3년 후 11.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YConsumer-retailing 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/05 17:43종가2026/07/03 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Redcare Pharmacy NV는 22명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gerhard SchwarzBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchSarah RobertsBarclays19명의 분석가 더 보기
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Recent Insider Transactions • Jul 02Key Executive recently sold €773k worth of stockOn the 26th of June, Michael Köhler sold around 12k shares on-market at roughly €64.40 per share. This transaction amounted to 4.0% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
공시 • Apr 17Redcare Pharmacy N.V. Announces Board Appointment, Effective April 15, 2026Redcare Pharmacy N.V. announced that at its Annual General Meeting held on April 15, 2026, the shareholders voted with an absolute majority for all agenda items, including the appointment of Anja Hendel, Max Müller and Peter Schmid von Linstow as new members of the Supervisory Board. The Supervisory Board now consists of Michael Köhler (Chairman), Peter Schmid von Linstow (Vice-Chairman), Stephan Weber, Anja Hendel and Max Müller.
Breakeven Date Change • Mar 05Forecast breakeven date pushed back to 2027The 8 analysts covering Redcare Pharmacy previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 92% to 2026. The company is expected to make a profit of €38.0m in 2027. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
공시 • Feb 07Redcare Pharmacy NV to Report Q2, 2026 Results on Jul 29, 2026Redcare Pharmacy NV announced that they will report Q2, 2026 results on Jul 29, 2026
공시 • Jan 28Redcare Pharmacy N.V. Supports Seamless Continuation Of Digital E-Prescription Journey With PoPP Draft SpecificationsRedcare Pharmacy N.V. reported that the national agency responsible for the digitalization of the healthcare system in Germany (gematik) has published the draft specifications of the PoPP (Proof of Patient Presence) module for remote care use case, including the digital redemption of e-prescriptions. PoPP is intended to replace the current VSDM++ patient card verification process on which Redcare’s CardLink solution is based. In its current draft form, the PoPP specifications confirm the continuation of a smooth, low-threshold digital process for e-prescription redemption using Redcare’s Shop Apotheke app in Germany. The ability to verify the eGK and a patient’s insured status without PIN on the app can continue now even more effectively, since an SMS for mobile number verification will no longer be required. Combined with the added optionality of using a digital ID in the future, this ensures stability, more flexibility and supports the continued adoption of digital solutions. The migration to PoPP is part of a broader modernization of Germany’s telematics infrastructure. The new technology raises security standards for data protection while enabling more flexible, software-based authentication options. Beyond enhanced security, this approach is expected to improve accessibility to healthcare services, particularly in remote and digital care settings. Following the publication of the final PoPP specifications for the remote care use case – anticipated in the First Quarter 2026 – Redcare Pharmacy will finalize the technical implementation within its Shop Apotheke app and secure the required regulatory approvals. The official rollout of PoPP Stufe 2 – Online Check-in by gematik is currently planned for the end of 2026. Redcare Pharmacy’s CardLink license extension remains valid until January 31, 2027, providing ample runway for a smooth and well-managed transition.
공시 • Jan 08Redcare Pharmacy NV to Report Fiscal Year 2025 Final Results on Mar 04, 2026Redcare Pharmacy NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Mar 04, 2026
공시 • Nov 12+ 1 more updateRedcare Pharmacy NV Designates Hendrik Krampe as Chief Financial Officer, Effective 1 December 2025Redcare Pharmacy announced that the Supervisory Board has designated Hendrik Krampe as Chief Financial Officer, effective 1 December 2025. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. The appointment of Hendrik Krampe is on the agenda of the Annual General Meeting to be held in April 2026 for consultation. Hendrik Krampe has twenty years of experience in the financial management of fast growing e-commerce businesses. Since 2014, he worked at Amazon where he held the role of Finance Director of the European marketplace business for the last eight years. From 2004 to 2014, Hendrik was at eBay in Germany as well as in the US in various roles including Finance Director of eBay’s Retail Media business. His broad expertise in efficiently scaling digital businesses, particularly marketplaces and Retail Media, complements Redcare Pharmacy´s strategy and will strengthen its core Rx and OTC business. The planned appointment of Hendrik comes at a time of continued growth momentum following strong third quarter results. It will support the company’s aim to increasingly capture economies of scale and improve profitability.
Reported Earnings • Oct 30Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: €719.2m (up 25% from 3Q 2024). Net loss: €7.24m (loss widened 4.8% from 3Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Consumer Retailing industry in Europe.
New Risk • Oct 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Significant insider selling over the past 3 months (€307k sold).
공시 • Oct 07Redcare Pharmacy NV to Report Q3, 2025 Results on Oct 29, 2025Redcare Pharmacy NV announced that they will report Q3, 2025 results on Oct 29, 2025
공시 • Sep 28Redcare Pharmacy NV Announces Stepping Down of Jasper Eenhorst from the Management BoardRedcare Pharmacy NV announced that Jasper Eenhorst will stepping down from the Managing Board, but will remain with the company until the end of this year to support a smooth transition to his successor.
Reported Earnings • Jul 29Second quarter 2025 earnings released: EPS: €0.46 (vs €0.21 loss in 2Q 2024)Second quarter 2025 results: EPS: €0.46 (up from €0.21 loss in 2Q 2024). Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up €13.6m from 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
공시 • Mar 19Redcare Pharmacy NV to Report Q2, 2025 Results on Jul 29, 2025Redcare Pharmacy NV announced that they will report Q2, 2025 results on Jul 29, 2025
공시 • Jul 30Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG on mid-May last year. Redcare Pharmacy NV (XTRA:RDC) completed the acquisition of MediService AG on mid-May last year.